Os Outcomes To Anlotinib In Patients (Pts) With Refractory Nsclc Of Both Wild-Type (Wt) And Mutant Egfr.Kai Li,Baohui Han, Q. Wang,Li Zhang,Jianhua Shi,Zhehai Wang,Ying Cheng,Jianxing He,Yuankai Shi,Weiqiang Chen,Xiuwen Wang,Yi Luo,Kejun Nan,Faguang Jin,Baolan Li,Jing WangJOURNAL OF CLINICAL ONCOLOGY(2018)引用 6|浏览26暂无评分AI 理解论文溯源树样例生成溯源树,研究论文发展脉络Chat Paper正在生成论文摘要